#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA3734311	B	Binding affinity to Gbetagamma in human HL60 cells assessed as inhibition of fMLP-stimulated GFP-PHAkt translocation to plasma membrane at 10 uM incubated for 5 mins prior to fMLP stimulation by Western blot analysis	Homo sapiens	3		cell-based format	Patent Bioactivity Data
2.	ALA3734313	B	Binding affinity to biotinylated Gbeta1gamma2 (unknown origin) by SPR analysis	Homo sapiens	1		protein complex format	Patent Bioactivity Data
3.	ALA3734315	B	Binding affinity to Gbetagamma in differentiated human HL60 cells assessed as inhibition of fMLP-stimulated Rac1 activation at 10 uM preincubated for 10 mins followed by fMLP challenge for 90 secs by Western blot analysis	Homo sapiens	3		cell-based format	Patent Bioactivity Data
4.	ALA3734316	F	Antiinflammatory activity in ip dosed Swiss-Webster mouse assessed as inhibition of carrageenan-induced paw edema administered 1 hr followed by carrageenan challenge measured 3 times every 2 hrs	Mus musculus	1		organism-based format	Patent Bioactivity Data
5.	ALA3734317	B	Binding affinity to Gbetagamma in differentiated human HL60 cells assessed as inhibition of fMLP-stimulated superoxide production at 10 uM preincubated for 10 mins followed by nitro blue tetrazolium addition for 5 mins and fMLP addition for 30 mins by NADPH oxidase assay	Homo sapiens	2		cell-based format	Patent Bioactivity Data
6.	ALA3734318	A	Effect on paw thickness in Swiss-Webster mouse at 100 mg/kg, ip administered 1 hr	Mus musculus	1		organism-based format	Patent Bioactivity Data
7.	ALA3734320	F	Antiinflammatory activity in Swiss-Webster mouse carrageenan-induced paw edema model assessed as inhibition of neutrophils recruitment in edematous fluid at 100 mg/kg, ip administered 1 hr followed by carrageenan challenge	Mus musculus	1		organism-based format	Patent Bioactivity Data
8.	ALA3734323	F	Antiinflammatory activity in Swiss-Webster mouse carrageenan-induced paw edema model assessed as reduction of paw exudate volume at 100 mg/kg, ip administered 1 hr followed by carrageenan challenge	Mus musculus	1		organism-based format	Patent Bioactivity Data
9.	ALA3734324	F	Antiinflammatory activity in differentiated human HL60 cells assessed as inhibition of fMLP-stimulated cell migration at 10 uM after 1 hr by Boyden chamber method	Homo sapiens	3		cell-based format	Patent Bioactivity Data
10.	ALA3734326	F	Antiinflammatory activity in primary human neutrophils assessed as inhibition of GM-CSF-stimulated chemotaxis at 1 uM after 1 hr by Boyden chamber method	Homo sapiens	2		cell-based format	Patent Bioactivity Data
11.	ALA3734327	F	Antiinflammatory activity in differentiated human HL60 cells assessed as inhibition of fMLP-stimulated chemotaxis by transwell assay	Homo sapiens	2		cell-based format	Patent Bioactivity Data
12.	ALA3734328	F	Antiinflammatory activity in primary human neutrophils assessed as inhibition of fMLP-stimulated chemotaxis after 1 hr by Boyden chamber method	Homo sapiens	1		cell-based format	Patent Bioactivity Data
13.	ALA3734329	F	Antiinflammatory activity in primary human neutrophils assessed as inhibition of IL8-stimulated chemotaxis after 1 hr by Boyden chamber method	Homo sapiens	1		cell-based format	Patent Bioactivity Data
14.	ALA3734332	F	Antiinflammatory activity in Swiss-Webster mouse assessed as inhibition of carrageenan-induced paw edema at 30 mg/kg, po administered 1 hr followed by carrageenan challenge measured at 3 hrs	Mus musculus	1		organism-based format	Patent Bioactivity Data
15.	ALA3734361	B	Inhibition of Gbetagamma-GRK2 interaction in mouse cardiomyocytes assessed as increase in contractility	Mus musculus	3		cell-based format	Patent Bioactivity Data
16.	ALA3734362	B	Inhibition of Gbetagamma-GRK2 interaction in mouse cardiomyocytes assessed as increase in isoproterenol-induced contractility	Mus musculus	3		cell-based format	Patent Bioactivity Data
17.	ALA3734371	T	Toxicity in C57/B16 mouse liver at 10 to 100 mg/kg/day administered for 2 weeks by histological analysis	Mus musculus	1		organism-based format	Patent Bioactivity Data
18.	ALA3734372	T	Toxicity in C57/B16 mouse lung at 10 to 100 mg/kg/day administered for 2 weeks by histological analysis	Mus musculus	1		organism-based format	Patent Bioactivity Data
19.	ALA3734373	T	Toxicity in C57/B16 mouse brain at 10 to 100 mg/kg/day administered for 2 weeks by histological analysis	Mus musculus	1		organism-based format	Patent Bioactivity Data
20.	ALA3734374	T	Toxicity in C57/B16 mouse heart at 10 to 100 mg/kg/day administered for 2 weeks by histological analysis	Mus musculus	1		organism-based format	Patent Bioactivity Data